Trial intelligence / Profile preview

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in Locally Advanced Pancreatic Cancer

ChiCTR2500106258Phase 2Recruiting

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start
Jul 2025
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of envafolimab and capecitabine in pancreatic cancer (PC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate. Started Jul 2025; status: recruiting.

02

Drugs

envafolimabcapecitabine
03

Conditions

pancreatic cancer (PC)

Beyond the preview

Go deeper on ChiCTR2500106258.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2500106258.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call